An open, prospective, multicenter study was designed to assess the efficacy and safety of
dydrogesterone in the post-laparoscopic treatment of
endometriosis in Indian patients. Ninety-eight patients suffering from minimal, mild, moderate or severe
endometriosis, with or without
infertility, who had undergone laparoscopy, were treated with
dydrogesterone 10 mg/day (or 20 mg/day in severe cases) orally from day 5 to day 25 of each cycle for 3-6 months.
Pelvic pain,
dysmenorrhea and
dyspareunia improved significantly (p < 0.05) after the first cycle of treatment. By the end of the sixth cycle, the reduction in
pelvic pain,
dysmenorrhea and
dyspareunia was 95%, 87% and 85%, respectively. The amount of menstrual
bleeding fell significantly (p < 0.05) after 2 months (-12%) and this significant reduction was maintained until the end of the study. The duration of
bleeding was also reduced significantly (p < 0.05) throughout the study, starting after the first month of treatment (-10%). A total of 21.1% of the patients were considered cured and 66.7% showed improvement. Overall,
dydrogesterone therapy was rated as excellent to good by 74% of patients and 70% of physicians. No adverse events were reported. In conclusion,
dydrogesterone is an effective and safe post-laparoscopic treatment for
endometriosis.